
A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults
Study Overview
The purpose of this Phase II Study is to determine the response rate of NFI patients with plexiform neurofibromas treated with Cabozantinib therapy using MRI scans.
Study Description
This phase II open label study will evaluate adolescents and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with cabozantinib (XL184).
Additional Information
Participants will not be paid for their participation.
- IRB Number: 1305011412 (1305005374) (CABOZANTINIB)
- Research Study Identifier: TX3396
- Principal Investigator: Michael Ferguson, MD
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required